Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,683.00+3.69%ETH$2,436.19+6.33%GOLD$4,072.20-0.02%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
LA

NASDAQ · LAB

Standard BioTools Inc.

Healthcare · Medical - Devices

$0.61

Up+$0.01 (+0.85%)

Updated Nov 4, 2026, 10:43 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
567.23M
P/E ratio
-4.4
Dividend yield
0.00%
52-week range
$0.59 – $1.72
Volume
1.27M
Avg. volume
1.65M

Price performance · LAB

LAB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

LAB closed at $0.61 after 21 trading sessions, down 15.40% for the selected period.

Last close
$0.61
Period change
-15.40%
Period low
$0.60
Period high
$0.72
Daily close
View OHLC price history
LAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.61$0.6257$0.6001$0.61081.27M
Nov 2, 2026$0.611$0.6275$0.60$0.60991.71M
Oct 30, 2026$0.6221$0.6248$0.60$0.611M
Oct 29, 2026$0.62$0.6298$0.6087$0.62445.8K
Oct 28, 2026$0.62$0.6299$0.6071$0.617741.71K
Oct 27, 2026$0.5957$0.6318$0.5881$0.61611.04M
Oct 26, 2026$0.62$0.62$0.5901$0.60644.2K
Oct 23, 2026$0.634$0.6498$0.5941$0.6056853K
Oct 22, 2026$0.63$0.6664$0.625$0.63561.2M
Oct 21, 2026$0.6254$0.6652$0.6254$0.65399.6K
Oct 20, 2026$0.635$0.6531$0.618$0.6373561.45K
Oct 19, 2026$0.62$0.6499$0.62$0.6433414.67K
Oct 16, 2026$0.6577$0.6584$0.6255$0.629647.38K
Oct 15, 2026$0.6301$0.6713$0.6301$0.6584485.72K
Oct 14, 2026$0.6406$0.6824$0.63$0.6321.19M
Oct 13, 2026$0.6588$0.6717$0.645$0.6589370.33K
Oct 12, 2026$0.69$0.69$0.6502$0.6578494.67K
Oct 9, 2026$0.677$0.7018$0.6612$0.6894652.21K
Oct 8, 2026$0.67$0.68$0.639$0.67031.91M
Oct 7, 2026$0.712$0.7416$0.675$0.67871.39M
Oct 6, 2026$0.7743$0.8016$0.7166$0.7221.4M

Latest LAB news

The latest Smart Investors Daily articles mentioning LAB.

Stock researchCompany · Overview

LAB research

Overview

Company profile and research snapshot.

Company profile

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.25
Implied upside
—
Analysts
—
LAB recent ratings
DateFirmRatingTarget
Nov 5, 2025TD CowenHold—
Feb 27, 2025KeybancSector Weight—
Oct 31, 2024TD CowenBuy—
Aug 1, 2024TD CowenBuy—
Apr 16, 2024TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED

BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED (“ARCHIMED”), a leading investment firm focused exclusively on healthcare industries. Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools, said, “ARCHIMED brings deep healthcare and life sciences expertise, a strong understanding of the mark

Yahoo · Sep 30, 2026

Standard BioTools Provides Update on Sale of Mass Cytometry Business

Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture’s Unsolicited Acquisition Proposal as SuperiorBOSTON, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”): Standard BioTools terminated its previously an

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By